Related Experiment Videos
Blood-brain barrier efflux transport
Pamela L Golden1, Gary M Pollack
1Drug Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Newark, Delaware 19880, USA.
Journal of Pharmaceutical Sciences
|September 2, 2003
Summary
Efflux transporters at the blood-brain barrier (BBB) restrict drug entry into the brain. Understanding these efflux transport systems is crucial for developing effective central nervous system (CNS) therapeutics.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Efflux transport at the blood-brain barrier (BBB) limits brain exposure to potential therapeutic agents.
- Specific transport systems at the brain-blood interface have been identified through advances in molecular and cell biology.
Purpose of the Study:
- To summarize the characteristics of efflux transporters at the BBB, including their location, specificity, and potential for inhibition.
- To present experimental approaches for assessing the impact of efflux transport on brain tissue uptake.
- To discuss the role of efflux transport in drug development for CNS agents.
Main Methods:
- Review of molecular and cell biology findings.
- Refinement of pharmacokinetic experimentation to assess transporter specificity and impact.
- Analysis of experimental approaches to determine efflux transport effects.
Main Results:
- Efflux transport significantly impacts brain tissue exposure to various compounds.
- Drug-drug interactions can occur at the BBB level due to efflux transport.
- Efflux transporter characteristics (location, specificity, inhibition) are summarized for the BBB.
Conclusions:
- Identifying efflux transport is vital for optimizing drug development for CNS-acting agents.
- Understanding BBB efflux transporters can improve therapeutic agent delivery to the brain.
- Efflux transport influences the pharmacodynamics of drugs targeting the central nervous system.